Month: September 2022

INTELLIGENT DRUGS. Quantum dots are used as tags for proteins in cell assays. Could they be used as tags to biological or small molecule drugs to develop a new generation of intelligent drugs that respond to their environment as a trigger to releasing their payload? http://lnkd.in/NkF_eu View in LinkedIn

Oliver Rothschild, the famous UK strategist, was the speaker at a Barcelona dinner of VCs last night. His message was that Spanish tech companies need to have worldwide strategic partnerships, and must move fast, as time is never on your side and is a luxury you cannot buy. Spain needs to trumpet its successes with worldwide PR, since it clearly has been under the radar too long. Now is the time to have a proactive effort to let the world know about the Catalan successes in innovation. View in LinkedIn

NEW DRUG COSTS for R&D since about 2000 by US Pharma companies sum to approximately 650 Billion USD, or 50-70 Bn USD annually. In addition, there has been less bang for the buck, as efficacy rates have slid south towards placebo. In contrast, VCs spend about 8-10 Bn USD annually on all sectors, with Biopharma being a part of that pie. Thus, for the ~900 new drugs (not NCEs) over that time period, the well over 7X annual spend by Big Pharma can be seen as squandered capital. It is a fortunate thing that most Big Pharma are experimenting with outsourcing/licensing their pipeline stuffers. http://lnkd.in/nYrdrN View in LinkedIn

NEW US PATENT ACT. A very usefully summary of this new IP landscape. http://lnkd.in/iS8ivT View in LinkedIn

CORPORATE TAXES: let's get real. There are armies of top law and accounting firms who charge large suns to wealthy corporations to structure "tax efficiency", which is gobbledygook for tax avoidance. This game is played by almost all major corporations and wealthy people. Remember Mitt Romney on personal taxes? And Warren Buffet admitting he paid less taxes than his secretarial staff? This is as old as the hills, so cut the moral outrage. http://lnkd.in/2xDwRS View in LinkedIn

FDA 483 Warning Letters are becoming quite frequent for pharmaceutical manufacturers, and the consequences can be dire in the worst case. Unfortunately, the "right way" to respond is complicated. For sure, there are legions of experts and consulting firms, who can be very valuable. But at the end of the day, after all the consultants and lawyers have had a go at the response, it is critical to ask if the company and the FDA are on the same planet in terms of communicating. Frequently not. http://lnkd.in/D4Z2TF View in LinkedIn

NEW VISION for visually impaired using a smart micro-camera on glasses which reads text aloud to the user and learns from the user to recognize new things. This brilliant innovation will undoubtedly help millions of people, relatively inexpensively, who suffer from visual defects. http://lnkd.in/RtR4YY View in LinkedIn

HEART ATTACK predictive markers have been sought for decades, and in the typical clinical lab, muscle markers are only diagnostic after the MI has occurred. Fatal or severe acute event predictive tests are well suited to Point-of-Care diagnostic systems for at-risk patients (family history, prior history, metabolic profile). http://lnkd.in/MgYtYw View in LinkedIn

NANO + PHARMA = OPPORTUNITY http://lnkd.in/qaURtg View in LinkedIn

3D PRINTING applied to orthotic devices. So far we have seen a number of medical applications for this cunning technology, and this will not be the end. http://lnkd.in/PCSXbg View in LinkedIn